The pharmaceutical industry remains critically dependent on plant-derived natural products, yet the supply of these complex molecules is perpetually threatened by the inherent biological instability of plant systems. For decades, the field has struggled to force undifferentiated plant cell cultures into the mold of consistent industrial fermentation, a strategy largely defeated by intrinsic biological stochasticity arising from epigenetic reprogramming, somaclonal variation, transcriptional noise, and systemic metabolic rigidity, as well as by a linear cost structure that prohibits pharmaceutical scalability. This literature-based review articulates a fundamental paradigm shift: the strategic decoupling of discovery from production. It argues that the genomic and epigenomic plasticity of plant cells—rather than being suppressed—should be deliberately induced and explored through stress elicitation to generate a “productive chaos” of chemical diversity for discovery. This expanded metabolic landscape is then decoded using single-cell–resolved multi-omics and spatial metabolomics to identify rare, elite producer states, alongside advanced artificial intelligence, molecular networking, and structure prediction to characterize novel bioactive candidates. Once identified, these biosynthetic pathways are functionally repatriated into defined, heterologous microbial hosts, engineered via systems-level metabolic and architectural optimization—including cofactor balancing, dynamic pathway control, subcellular compartmentalization, and cytochrome P450–reductase stoichiometry—to achieve stable, high-titer manufacturing. By integrating high-throughput discovery, AI-guided strain design, techno-economic analysis, and regulatory Quality-by-Design principles, this discovery–production decoupling resolves the long-standing tension between biological complexity and industrial rigor. This framework transforms the economics of natural product supply, transitioning from the low-CAPEX/high-OPEX trap of extraction to the high-CAPEX/low-OPEX scalability of fermentation, offering a scientifically grounded, commercially viable, and regulatorily tractable pathway to unlock the full therapeutic potential of the plant kingdom.
Dexter Achu Mosoh (Fri,) studied this question.